Immune cells take on childhood leukemia: new hope for relapsed patients
NCT ID NCT07406178
First seen Feb 14, 2026 · Last updated May 12, 2026 · Updated 13 times
Summary
This early-phase trial tests an experimental therapy called JY509, made from donor natural killer (NK) cells, in 18 children whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The goal is to see if these immune cells are safe and can help control the disease. Because this is a very early study, the main focus is on side effects, not yet on a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PEDIATRIC B-ALL are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.